• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Neuroimmunology: Official Bulletin of the Research Committee on Neuroimmunology of the World Federation of Neurology >Complement regulatory proteins (CD46, 55 and 59) expressed on Schwann cells: Immune targets in demyelinating neuropathies?
【24h】

Complement regulatory proteins (CD46, 55 and 59) expressed on Schwann cells: Immune targets in demyelinating neuropathies?

机译：在雪旺细胞上表达的补体调节蛋白（CD46、55和59）：脱髓鞘神经病的免疫靶点？

获取原文
获取原文并翻译 | 示例
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Given their localization and important role in regulating complement, complement regulatory proteins may act as target antigens and their antibodies as biomarkers in demyelinating neuropathies. We investigated the binding of autoantibodies to complement regulatory proteins (CD46, 55 and 59) in demyelinating diseases. In 42 acute inflammatory demyelinating polyneuropathy, 23 chronic inflammatory demyelinating polyneuropathy, 13 acute motor axonal neuropathy, 71 multiple sclerosis, and 19 neuromyelitis optica patients as well as 55 healthy controls, we were unable to detect significant titers of antibodies to CD46, CD55 and CD59. These autoantibodies are unlikely to be biomarkers in acute and chronic inflammatory demyelinating polyneuropathies.
机译：鉴于它们的定位和其在调节补体中的重要作用，补体调节蛋白可在脱髓鞘性神经病中充当靶抗原，而其抗体充当生物标志物。我们研究了脱髓鞘疾病中自身抗体与补体调节蛋白（CD46、55和59）的结合。在42例急性炎性脱髓鞘性多发性神经病，23例慢性炎性脱髓鞘性多发性神经病，13例急性运动性轴索神经病，71例多发性硬化症和19例视神经脊髓炎患者以及55名健康对照中，我们无法检测到显着滴度的CD46，CD55和CD59抗体。这些自身抗体不太可能是急性和慢性炎症性脱髓鞘性多发性神经病的生物标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号